Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01226654 · ClinicalTrials.gov registry record · NA

Quantitative Imaging and Proton Spectroscopy in Multiple Sclerosis

A NA study, sponsored by NYU Langone Health.

Terminated
Registry status
NA
Development phase
69
Enrollment target

NCT01226654 is a NA study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 69 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01226654, a NA study, was terminated before completion, sponsored by NYU Langone Health.

TERMINATED
Registry status
NA
Development phase
69 participants
Enrollment target

Study Summary

The primary purpose of this study is to detect changes in the brain that may be associated with multiple sclerosis. Results will be compared to age matched controls. Investigators will assess lesions by measuring T2 and T1 enhanced lesion volumes and magnetization transfer ratio histogram parameters (MTRHP) in patients with relapsing-remitting and secondary-progressive disease. This data will be correlated to total brain parenchymal volume as well as identifying the effect of MS lesions on the gray and white matter, volumetric disability, including Kurtzke Expanded Disability Status Scale (EDSS) and a specific battery of neuropsychological tests. Quantitative analysis of whole brain N-acetylaspartate (WBNAA), a reproducible measure of viable neuron number, using 1H MRS and compare the results to age-matched controls over duration of 5 years.

Interventions

  • DEVICE Magnetic Resonance Imaging

Trial Details

FieldValue
Enrollment Target 69 participants
Start Date 1991-08
Est. Completion 2016-04
Phase NA

Sponsor

NYU Langone Health

1,164 total trials

What the Registry Record Tells You About NCT01226654

The ClinicalTrials.gov registry entry for NCT01226654 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Magnetic Resonance Imaging is the first listed.

NCT01226654 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01226654 about?

NCT01226654 is a clinical study titled "Quantitative Imaging and Proton Spectroscopy in Multiple Sclerosis". The primary purpose of this study is to detect changes in the brain that may be associated with multiple sclerosis. Results will be compared to age matched controls. Investigators will assess lesions by measuring T2 and T1 enhanced lesion volumes and magnetization transfer ratio histogram parameters...

What is the current status of trial NCT01226654?

This trial is currently terminated. It is a NA study. The enrollment target is 69 participants. The study started on 1991-08. Estimated completion is 2016-04.

What interventions are being tested in trial NCT01226654?

The interventions under investigation include: Magnetic Resonance Imaging (DEVICE).

Who is sponsoring clinical trial NCT01226654?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.